PODD Insulet Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:00
Aug 05
Aug 05
Management is cutting full-year revenue guidance and citing execution failures in the Type 2 market, acknowledging a lack of visibility into retention/utilization trends.
HIGH
19:52
Jun 23
Jun 23
The author screens for low forward PEG ratios among high-growth gainers but does not state.
The author screens for low forward PEG ratios among high-growth gainers but does not state a personal position or forward call on any ticker.
LOW
13:12
May 06
May 06
The author mocks the T2 diabetes thesis for PODD.
The author mocks the T2 diabetes thesis for PODD, implying the stock is failing and calling it dead tech.
HIGH
13:11
May 06
May 06
The author mocks the T2 diabetes thesis for PODD.
The author mocks the T2 diabetes thesis for PODD, implying it is failing and questioning those who believed in it.
HIGH
12:00
May 06
May 06
Strong Q1 results, with 30% growth and robust margin expansion, prompt raising full-year guidance, indicating high confidence in sustained momentum.
HIGH
23:55
Apr 23
Apr 23
Insulet too expensive due to GLP-1.
Insulet is the most declined stock in healthcare and remains too expensive because the GLP-1 drug threat is existential.
MED
13:00
Feb 18
Feb 18
Despite guided deceleration from comps, Insulet maintains strong growth outlook with 20-22% full-year revenue growth and continued margin expansion, indicating confidence in sustained demand.
HIGH
About PODD Analyst Coverage
Buzzberg tracks PODD (Insulet) across 4 sources. 0 bullish vs 0 bearish calls from 5 analysts. Sentiment: evenly split. 7 total trade ideas tracked. Latest voices: Ashley McEvoy, Minnvestor, TheLAPurchaser.